Recent years have witnessed the discovery of several classes of noncoding RNAs (ncRNAs), which are indispensable for the regulation of cellular processes. Many of these RNAs are regulatory in nature with functions in gene expression regulation such as piwi-interacting RNAs, small interfering RNAs and micro RNAs. Long noncoding RNAs (lncRNAs) comprise the most recently characterized class. LncRNAs are involved in transcriptional regulation, chromatin remodeling, imprinting, splicing, and translation, among other critical functions in the cell. Recent studies have elucidated the importance of lncRNAs in hematopoietic development. Dysregulation of lncRNA expression is a feature of various diseases and cancers, and is also seen in hematopoietic malignancies. This article focuses on lncRNAs that have been implicated in the pathogenesis of hematopoietic malignancies.
Introduction
Blood cell development is a complex and highly ordered process that occurs as successive waves of fetal and embryonic hematopoiesis before definitive adult hematopoiesis in mammals. The bone marrow is the site of adult hematopoiesis in mammals, leading to the genesis of all the major lineages in the blood including lymphoid cells, myeloid cells, as well as anucleated red blood cells and platelets. This complex developmental process is intimately connected with the regulation of gene expression, as hematopoietic stem cells (HSCs) become successively committed to one or the other developmental lineage [1] . This system has been extensively studied in model organisms, including mice, with several important insights. Hierarchical models of development have been established, with loss of developmental potential characterizing each successive step. Several models of development exist and specify different relationships between progenitor cells in the bone marrow [1] [2] [3] [4] [5] [6] [7] . Most models include separate hierarchies for developing myeloid and lymphoid cells, with the former giving rise to erythrocytes, platelets, granulocytes, and monocytes, and the latter giving rise to B-and T-lymphocytes [2, 6] . Importantly, specific transcriptional regulators, which tightly control gene expression, are known to function at different branch points in the hematopoietic hierarchy [8] [9] [10] . In addition, changes in chromosomal accessibility and epigenetic regulation play highly important roles. New discoveries showing that noncoding elements of the genome can also control gene expression may help us better understand both hematopoietic development and cancer.
Long noncoding RNAs (lncRNAs) are a recently described class of noncoding transcripts, the importance of which is still being recognized [11] [12] [13] [14] [15] . These RNAs are 200 nucleotides in length, transcribed by RNA polymerase II or III, undergo splicing and are usually polyadenylated. They generally lack open reading frames (ORFs) of significant length, although a few may contain small ORFs within one or more alternative splice forms [16, 17] . These transcripts show functional and genomic conservation in vertebrates, despite rapid sequence evolution [18] . Over 10,000 lncRNAs have been identified so far; some of these are well described, while the majority require further characterization [15, [18] [19] [20] [21] [22] [23] . These transcripts can be classified by their position relative to neighboring protein coding genes: sense, antisense, intronic, exonic, or intergenic/intervening [24, 25] . LncRNAs are important regulators of a wide variety of cellular processes with distinct functions that differ based on the cellular compartment in which they are found. Nuclear and cytoplasmic transcripts can regulate gene expression at the transcriptional or translational level, respectively ( Figure 1 ). They can recruit chromatin-remodeling complexes, regulate transcription, promote messenger RNA (mRNA)translation, and stabilize mRNA transcripts to prevent or induce decay ( Figure 1A -D) [26] [27] [28] [29] [30] . Additionally, they can influence changes in the spatial conformation of chromosomes, imprinting, and splicing ( Figure 1E ) [17, [31] [32] [33] [34] . A few loci that produce lncRNAs can also produce small biologically active peptides, and the notation of such loci as "noncoding" can therefore be debated [17] . Nonetheless, a variety of noncoding functions can be ascribed to the majority of lncRNAs; some can serve as sponges competing for microRNAs, and some even harbor microRNAs within their transcripts ( Figure 1F ) [35] [36] [37] . The fact that lncRNAs are intrinsically involved with a diverse array of cellular mechanisms attests to potentially pivotal roles in development in general, and to hematopoiesis in particular.
Indeed, several recent studies have revealed that lncRNAs can regulate hematopoietic development, influencing differentiation, proliferation, and cell survival. They have important regulatory roles at many developmental stages including, the determination of HSC fate, and the differentiation of progenitor and precursor blood cells of lymphoid, myeloid and erythroid lineages [38] [39] [40] [41] [42] [43] . The relatively well-known lncRNA, H19, is involved in maternal imprinting, and was one of the first lncRNAs described to function in adult HSC quiescence. H19 is highly expressed in long-term HSCs, with gradual downregulation in short-term HSCs. This transcript promotes HSC quiescence by regulating the Igf2-Igf1r pathway [38] . Thymic (T-lymphocyte) specific lncRNAs have also been described. One example of this is thymus specific noncoding RNA (Thy-ncR1), a cytoplasmic riboregulator of Microfibrillarassociated protein (MFAP) degradation [39] . B-cell Integration Cluster (BIC), which harbors miR-155-5p and miR-155-3p, is critical in hematopoietic lineage differentiation and in activation of mature B-cells [40, 44] . In the myeloid lineage, HOX antisense intergenic RNA myeloid 1 induces the expression of myeloblast differentiation genes, including HOXA1 and HOXA4 [41] . Similarly, the Eosinophil Granule Ontogeny lncRNA is involved in stimulating eosinophilic differentiation of CD34þ progenitor cells by regulating protein expression [42] . During murine erythroid differentiation, the Erythroid Pro-Survival lincRNA promotes terminal differentiation of mature erythrocytes by inhibiting pro-apoptotic gene Pycard [43] . Hence, lncRNAs play a variety of roles in controlling different steps in hematopoietic differentiation, including the maintenance of HSCs and the differentiation of myeloid, erythroid, and lymphoid lineages.
The disruption of the highly ordered differentiation of hematopoietic elements by somatic mutations leads to cancers of the hematopoietic system. These diseases can broadly be divided into lymphoid and myeloid diseases. Also, these malignancies can be thought of as diseases derived from the bone marrow, which occur clinically as a primarily 'hematologic' (blood and bone marrow) presentation, or as diseases of mature lymphoid organs, which present primarily as solid tumors of lymph nodes and other tissues. In this review we will focus on bone marrowderived hematopoietic malignancies, which include diseases derived from both lymphoid and myeloid progenitor cells. These diseases demonstrate many different patient presentations, and current classification systems for the diseases are based both on clinical background and on insights gained from analyses of the molecular alterations. Modern studies increasingly emphasize the role of lncRNAs as important elements in hematopoietic malignant progression (Table 1) . Their modulation of a vast amount of cellular processes, especially those involved in differentiation and cell fate, ties them closely to the pathogenesis of these diseases. In the sections below, we will discuss lncRNAs that are involved in myeloid derived diseases, including myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML). We will also discuss a disease of lymphoid origin in the context of acute lymphoblastic leukemia (ALL), which constitutes the most important bone marrow-derived lymphoid malignancy and the most common childhood malignancy.
Myelodysplastic syndromes
MDs are a heterogeneous group of clonal hematopoietic disorders that are characterized by decreases in mature peripheral blood cells (PBCs), or cytopenias. This is thought to result from a clonal set of somatic mutations that confer a selective advantage on early progenitor cells, but concurrently inhibit their ability to differentiate into mature blood cells. This expansion of Long noncoding RNAs in hematopoietic malignancies | 229
'immature' cells contrasts with MPN and AML profiles, in which different stages of myeloid development are observed to be the origin of malignant transformation. Recent work has implicated a number of pathways that are involved in the pathogenesis of this group of diseases. Perhaps the best-characterized MDS is 5q-syndrome, which results from the loss of the long arm of chromosome 5 in humans [77] . It has been determined that several coding and noncoding genes that are located in this genomic area are important in the pathogenesis of 5q-syndrome. Indeed, microRNA-146a is downregulated as a consequence of this deletion, and experimentally induced deficiency of this microRNA results in myeloproliferative and myelodysplastic phenotypes [78] [79] [80] . However, several other forms of MDS are known to exhibit a variety of mutations based on recent high throughput sequencing studies. These include mutations in splicing factor genes, raising the idea that MDS results from global changes in RNA splicing [81, 82] . DNA methylation is also affected, causing global changes in gene expression regulation, which result in the observed phenotypes of hematopoietic progenitor cell dysplasia and peripheral cytopenias [83] . This work has now extended into analysis of incRNAs in MDS, with a few specific transcripts, such as X-inactive-specific transcript (XIST) and maternally expressed 3 (MEG3), involved in disease pathogenesis.
Although XIST was one of the earliest described functional noncoding transcripts, it is only now beginning to be appreciated in hematopoietic homeostasis. XIST is located on the X chromosome along with multiple noncoding transcripts, which together are crucial for regulation of X chromosome inactivation by imprinting [46, 70, [84] [85] [86] . Inactivation of the X chromosome occurs via recruitment of protein complexes for epigenetic modification of histones, ultimately silencing target loci ( Figure 2 ) [87] . Importantly, several studies have shown that X chromosome aberrations are involved in human cancers [88] [89] [90] . Recently, Yildirim et al. showed that conditional knockout of Xist in HSC of female mice caused highly aggressive myeloid neoplasms with 100% penetrance. Features of MDS were observed in the bone marrow, including hypolobated megakaryocytes and binucleated erythroid precursors. In the myeloid lineage, they observed hypogranularity and abnormal lobation in neutrophils and myelocytes, reminiscent of additional morphologic changes in human MDS. Lastly, circulating erythroid precursors were present and showed nuclear irregularities [45] . However, this likely does not represent a pure MDS phenotype. Rather, mice presented hyperplasia of all splenic compartments. In the bone marrow, mice had abnormal mitotic figures including multipolar mitoses, myeloid hyperplasia, and increased fibroblasts. In the peripheral blood, white blood cell counts were elevated when compared with wild-type females, including increased numbers of immature myelomonocytic cells, reminiscent of manifestations seen in chronic myelomonocytic leukemia. Gene expression analyses demonstrated reactivation of several X-chromosome encoded genes; this abnormal increase in gene dosage was postulated to explain the formation of myeloid malignancies. These findings highlight a role for lncRNAs in the normal development of bone marrow progenitors and demonstrate, in vivo, the pathological effects of deletion of a lncRNA.
MEG3 is a myeloid related lncRNA that has been implicated in multiple human malignancies [91] . MEG3 is important for Mouse double minute 2 (MDM2) down-regulation and for enhanced p53 binding to promoter regions of genes, such as the growth differentiation factor 15 promoter [48] . Additionally, it is believed that MEG3 regulates genes by recruiting Polycomb Repressive Complex 2 (PRC2) for epigenetic silencing of targets [92] . Its locus is tightly regulated by modifications in its differentially methylated regions (DMRs), and suppression of MEG3 expression in solid tumors occurs by hypermethylation of the DMRs [93] . In a cohort of 85 patients with MDS or AML, it was shown that 35% of MDS patients had aberrant hypermethylation of the MEG3 promoter region. These modifications trended with decreased overall patient survival [47] . These data once again strongly suggest that loss of a lncRNA can contribute to MDS pathogenesis and/or disease severity.
Although the number of studies is still small, these data provide compelling evidence for lncRNAs playing some role in MDS pathogenesis. Global profiling studies of lncRNA expression, and/or reanalysis of existing datasets with standardized algorithms designed to identify known and novel lncRNAs, may help us further understand the role of noncoding elements in this incompletely understood disease.
Myeloproliferative neoplasms
In contrast to MDS, MPN are characterized by increased mature PBC of one or more lineages, with the clonal proliferative advantage directing proliferation and differentiation of the erythroid, myeloid, or megakaryocytic lineages. The study of molecular pathogenesis and therapy in MPNs has been an area of rapid progress. MPN are classically divided into several subsets based on the lineage primarily affected. For example, the MPN Polycythemia Vera (PV) is a disease of red blood cell overproduction, while the MPN, known as essential thrombocythemia (ET), is a disease of platelet overproduction. Many MPNs arise from mutations in tyrosine kinases, resulting in constitutive activation of pro-survival and proliferation signaling pathways, within certain primitive hematopoietic elements. The prime example in this category is chronic myelogenous leukemia (CML), a chronic form of leukemia in which the understanding of genetic abnormalities has led to striking new therapies, and improved patient outcome. CML is caused by a translocation between chromosomes 9 and 22, which results in the production of a chimeric fusion protein, BCR-ABL, a constitutively activated tyrosine kinase [94] . This fusion protein can cause a CML-like disease when overexpressed in mouse bone marrow. Remarkably, targeted therapies against BCR-ABL, such as treatment with the tyrosine kinase inhibitor Imatinib, have resulted in prolongation of disease free and overall survival in patients [95, 96] . The gene expression changes in CML are also an area of active investigation, and it is likely that lncRNAs are a part of the BCR-ABL-driven gene expression program.
Recently, Guo et al. carried out a comprehensive study of lncRNA transcripts in human CML cells [49] . Specifically, they used a lncRNA omplementary DNA microarray to identify dysregulated transcripts in K562 cell lines transduced with BCR-ABL small hairpin RNA (shRNA) or luciferase shRNA. The analysis revealed that 338 lncRNAs were upregulated and 108 were downregulated after knockdown of BCR-ABL. Among the most significantly dysregulated lncRNAs was Beta Globin Locus 3 (BGL3), which may play a role in regulating c-globin expression [97] . Expression of BGL3 was elevated in human cell lines with BCR-ABL inhibition. In the presence of imatinib, ectopic expression of the transcript reduced cell viability, while shRNA mediated knockdown increased it. In BGL3 transgenic mice, bone marrow transformation by BCR-ABL was impaired. Additionally, the transcript acted as a competitive endogenous RNA for binding of microRNAs that regulate Phosphatase and tensin homolog (PTEN) expression (Figure 3) . Hence, it is likely that the dysregulation of this tumor-suppressor lncRNA is involved in CML progression [49] .
In addition to its aforementioned role in normal hematopoietic development, recent studies have shown a role for H19 in myeloid neoplasms. As noted before, H19 regulates the imprinting of its chromosomally adjacent gene, insulin-like growth factor 2 and regulates murine genes Igfr2 and Dlkl in trans [98, 99] . This transcript has been implicated in various cancers as an oncogene or tumor suppressor, depending on the context [52, 100] . Additionally, H19 harbors miR-675 in its first exon, which is known to regulate Igf1r [53] . Thus H19 acts as a lncRNA or a microRNA precursor in different cellular processes [36] . Bock et al. examined expression levels of this lncRNA in normal bone marrow cells, as well as tissues from patients with different chronic myeloproliferative disorders, including PV, ET, CML, cellular phase primary myelofibrosis, fibrotic phase primary myelofibrosis, and chronic myelomonocytic leukemia (CMML). Quantitative real time polymerase chain reaction (qRT-PCR) revealed that all of these patient samples had reduced expression of H19 when compared with normal control cases [50] . Similarly, Tessema et al. analyzed H19 expression in bone marrow biopsies and peripheral blood samples from normal donors, CMML patients, CML patients, and AML patients, finding reduced expression when compared with the healthy controls [51] . Conversely, studies by Guo and colleagues demonstrated that the expression of H19 is BCR-ABL kinase dependent in a BCR-ABL-positive cell line, and in primary CML cells derived from patients [101] . Knockdown of H19 in K562 cells induced apoptosis, and in mice, it inhibited xenograft growth. Functional studies revealed that H19 expression is regulated by v-Myc in CML cell lines. These data suggest that H19 is required for tumorigenesis induced by BCR-ABL, acting in this context as an oncogene [101] . Further studies on H19 need to be carried out to fully understand its role in MPN, and these studies highlight the importance of studying lncRNA function in a cell-type appropriate context.
Acute myeloid leukemia
In AML, a uniform population of blast cells replaces the normal heterogeneous population of maturing hematopoietic progenitor cells within the bone marrow. These cells are myeloid progenitor cells, and are thought to derive from multipotent myeloid-biased progenitor cells, or from committed myeloid progenitors such as the common myeloid progenitor (CMP). AML is characterized by a bimodal incidence in terms of age, and is most common in older adults. Much work has gone into characterizing the molecular changes that are present in AML, and recurrent cytogenetic and molecular abnormalities are present in a large portion of AML patients. Many of these changes result in a dramatic proliferative advantage and/or an arrest in differentiation, contributing to the massive proliferation of blast cells that is seen in AML. Gene expression changes in AML are widespread and involve many different pathways. Therefore, it is likely that coding and noncoding elements play important roles in AML pathogenesis.
As a disease, AML is most devastating in older adults, who have a poor prognosis and low overall survival rates [102] [103] [104] . Although 50-55% of patients have chromosomal abnormalities, 45-50% of patient cases are cytogenetically normal (CN-AML) [103] [104] [105] . Nonetheless, CN-AML carries frequent somatic mutations in several oncogenes. Among these frequently mutated genes are nucleophosmin 1 (NPM1), Fms-related tyrosineprotein kinase-3 (FLT3) and cytosine-cytosine-adenosineadenosine-thymidine box motif (CCAAT)/enhancer-binding protein alpha (CEBPA) [105] [106] [107] . Garzon et al. examined lncRNA expression in CN-AML patients to determine any correlations with known mutations. Indeed, lncRNA expression profiles segregated with mutations in the aforementioned genes. [61] . In NPM1-mutated cases, they observed upregulation of antisense transcripts of HOX genes, and of the plasmacytoma variant translocation 1 (PVT1) lncRNA. It has been shown that PVT1 is required for high-level expression of MYC in human cancer cells, and hence may play a pathogenetic role in AML [108] . In addition, the Wilms tumor 1 antisense RNA (WT1-AS) was found exclusively in FLT3-ITD (Internal tandem duplications)-mutated cases. The WT1-AS transcript is alternatively spliced in AML and ALL samples [68] . Lastly, among the upregulated lncRNAs in the CEBPA mutated cases was urothelial cancer associated 1 (UCA1), the role of which in AML has been recently studied [61, 62] .
UCA1 lncRNA was first identified by a comprehensive expressed sequence tag analysis of candidate markers in patients with transitional cell carcinoma of the bladder [109] . Interestingly, this lncRNA can cause chemoresistance in bladder cancer by upregulating the Wnt signaling pathway [110] . UCA1 has also been implicated in a variety of malignancies, such as colorectaral cancer, and breast cancer [63, 111] . In AML, Hughes et al. studied the effects of a dominant negative isoform of CEBPA, known as CEBPA-p30 [62, 112] . Genome-wide transcriptome analysis of K562 cells with inducible CEBPA-p30, identified lncRNAs that are negatively regulated by the mutant protein [62] . Among the significantly dysregulated transcripts . Cases with biallelic CEBPA mutations demonstrated an increase in UCA1 expression, further supporting the idea that UCA1 expression depends on mutant CEBPA. Taken together, these data suggest that UCA1 acts as an oncogenic lncRNA in CN-AML [62] .
Another recent addition to the AML-related lncRNA profile is the antisense noncoding RNA in the INhibitors of CDK4 (INK4) locus (ANRIL), a polyadenylated cell-cycle related lncRNA that is transcribed antisense to p15
INK4b [113] . This transcript has multiple isoforms that are transcribed in an antisense orientation to the INK4 locus. One variant, p15AS, was isolated from two AML cell lines. p15AS was up-regulated in 11 of 16 AML and ALL primary samples [54] . This lncRNA was responsible for silencing of p15 INK4b by regulating H3K9me2 and H3K4me2 levels at the promoter regions, prompting heterochromatin formation. It is likely that p15AS recruits PRC2 because Enhancer of zeste homolog 2 (EZH2) and Suppressor of zeste 12 (SUZ12) (components of the PRC2 complex) were required for stable silencing of the locus. Kotake et al. recently demonstrated that ANRIL does in fact recruit PRC2 by binding to SUZ12 to silence tumor suppressor genes in the p15 INK4b locus, indicating its role as an oncogene ( Figure 5 ) [55] . In addition to being dysregulated in MDS, aberrant hypermethylation of the DMRs in the MEG3 promoter was seen in 48% of AML patients. These findings correlated significantly with decreased survival in AML [93] . The finding of hypermethylation of the MEG3 promoter was confirmed in a second study examining 40 patients with AML [114] . Further study of MEG3 in AML is imperative for greater understanding of its role in pathogenesis.
One of the best-studied lncRNAs is HOX transcript antisense RNA (HOTAIR). This lncRNA is expressed from the HOXC locus, and is a trans-acting repressor of genes in the HOXD locus [26] . Specifically, it recruits PRC2 to the target loci, and is required for H3K27me3 of chromatin associated with the HOXD locus. This lncRNA is crucial for homeotic and skeletal development [115] . In addition, this transcript has been implicated in different cancers and contributes to breast cancer progression by "reprogramming" the chromatin state [116] [117] [118] [119] . Recently, Xing et al. showed increased expression of HOTAIR in leukemic cells lines and primary AML blasts [71] . Patients with high HOTAIR expression showed the worst clinical outcome. shRNAmediated knockdown of HOTAIR inhibited cell growth, caused apoptosis, and reduced the number of colony formation units. Notably, HOTAIR regulates cellular homolog of the feline sarcoma viral oncogene v-kit (c-KIT) expression by acting as a competitive endogenous RNA. It binds to miR-193a, which targets c-KIT. These results suggest an oncogenic role for HOTAIR in AML, in addition to its known role in epithelial cancers.
While AML is not as common in children as it is in adults, inherited mutations can cause a predisposition to this malignancy. Particularly, children with Down Syndrome (DS) have an increased risk of developing acute megakaryoblastic leukemia (AMKL), a type of AML. Interestingly, patients with DS-AMKL have a much better prognosis than cases of non-DS-AMKL [120] [121] [122] . Klusmann et al. reported that an oncogenic microRNA (oncomir), miR-125b-2 located on chromosome 21, is highly expressed in patients with DS-AMKL when compared with non-DS-AMKL cases. This microRNA is located within the same locus as two lncRNAs, megakaryocytic oncogenic noncoding RNA, aka MIR199AHG (MONC) (also known as MIR199AHG (miR199a host gene, aka MONC)) and miR-100 host gene (MIR100HG) [123] . The roles of these two lncRNAs were examined in AMKL pathogenesis [74] . These transcripts are mainly nuclear, are highly expressed in AMKL blasts, and their expression was correlated with their corresponding microRNA clusters. Knockdown of MONC and MIR100HG resulted in impeded cell growth in both cell lines and primary patient samples. Using a lentiviral lncRNA vector, which purportedly conserves RNA secondary structure, MONC was overexpressed in hematopoietic stem and progenitors cells obtained from cord blood. This resulted in arrested myeloid differentiation, and enhanced the proliferation of erythroid progenitor cells. Taken together these data show that MONC and MIR100HG play important roles in AMKL leukemic growth, independent of the micro RNA (miRNA)clusters that they harbor [74] . Together, these studies demonstrate functional roles for several lncRNAs in AML and highlight a variety of cellular functions for these lncRNAs.
B-Acute lymphoblastic leukemia
Acute leukemia can be derived from lymphoid and myeloid progenitors, which constitute the traditional two branches in the hierarchy of hematopoietic development. ALL can be derived from B-or T-cell progenitors, with the former being much more common. B-acute lymphoblastic leukemia (B-ALL) is a disease with a bimodal distribution and is the most common malignancy in children. Years of research have identified recurrent cytogenetic abnormalities in B-ALL, including four common translocations, fusion of the ETS variant 6 (ETV6) and RUNX1 genes (ETV6-RUNX1), BCR-ABL, mixed lineage leukemia (MLL) rearrangements and fusion protein of E2A and PBX1 genes (E2A-PBX1), which account for about 30% of cases [124] . In addition, deletion of genes that are important in B-cell development, such as Paired Box 5 (PAX5) and Mouse double minute 2 (IKZF1), have also been noted in many cases [125] [126] [127] [128] . Together these findings implicate that abnormal expression of B-cell maturation genes, as well as ectopically expressed genes, can contribute to the pathogenesis of B-ALL. Recently, these gene expression changes have shown to include noncoding RNA. Indeed certain microRNAs, such as miR-21, have now been recognized as capable of driving ALL in mouse models [129] .
Little is known about the role lncRNAs play in the pathogenesis of ALL. Recently, two important profiling studies have given us insights on how these transcripts are involved in this important hematopoietic malignancy [22, 23] . Fang and colleagues carried out a genome-wide lncRNA expression study on MLL-rearranged (MLL-r) ALL patient samples [23] . They identified 111 lncRNAs that were differentially expressed in MLL-r ALL samples when compared with normal bone marrow samples. Additionally, unique expression patterns between the different MLL translocations were observed. lncRNA expression correlated with certain broad categories of genes, including known MLL-fusion target proteins, such as HOXA9 and MEIS1. Functional studies with small interfering RNAs (siRNAs) demonstrated that particular lncRNAs can affect cellular proliferation and apoptosis.
Fernando et al. expanded the scope of lncRNAs in B-ALL by looking at patient samples with several different translocations (E2A-PBX, TEL-AML1, MLL-r, BCR-ABL, and CN-ALL in this section, or just cytogenetically normal cases) [22] . Unbiased microarray profiling of human B-ALL samples revealed that lncRNA expression correlated with the specific cytogenetic abnormalities. This karyotype discrimination was confirmed by qRT-PCR of four transcripts, termed B-ALLassociated long RNAs (BALRs). Among these lncRNAs, BALR-2 expression correlated significantly with poor overall survival and reduced patient response to prednisone treatment. Interestingly, functional studies carried out in human and murine B-ALL cell lines demonstrated that BALR-2 has an important role in regulating cell proliferation, apoptosis and sensitivity to glucocorticoid treatment. Most importantly, a pivotal role for BALR-2 in the glucocorticoid response pathway was uncovered, with BALR-2 expression negatively regulating the expression of cellular homolog of the viral oncoprotein v-jun (JUN) and its pro-apoptotic target bcl-2 interacting mediator (BIM). Notably, a different lncRNA, growth arrest-specific 5 has been implicated in lymphoma, and acts as a decoy for the glucorticoid receptor, causing transcriptional silencing of target genes ( Figure 1E ) [130] [131] [132] [133] [134] [135] . It is possible that BALR-2 may also downregulate glucocorticoid receptor-mediated signaling; however, the mechanism has not yet been delineated. These results support the importance of BALR-2 in B-ALL leukemogenesis, prognosis and treatment.
As mentioned previously, Yu et al. showed that ANRIL was upregulated in both AML and ALL samples. In this study, ANRIL acted as a tumor promoting lncRNA, in particular, regulating the expression of p15
INK4b and p16 INK4a cell cycle inhibitors ( Figure 5 ) [54, 55] . Iacobucci et al. carried out a study using ALL PBCs, compared with normal nonmalignant PBCs, that showed a clear association between ANRIL and a known BCR-ABL-related ALL nucleotide polymorphism [75] . Similar to what is seen in AML, these data suggest a role as a tumor promoting lncRNA for ANRIL by epigenetic regulation of cell-cycle inhibitor genes.
Conclusions
In a remarkably short time, there has been much progress into understanding the molecular and cellular function of lncRNAs, as well as their involvement in various physiological and pathological processes. This review has focused mainly on the importance of a select few lncRNAs that have been studied in the pathogenesis of hematopoietic malignancies (Table 1) . For the most part, the data are largely correlative and clinically derived, but there have been a few important mechanistic studies. It seems fair to say that, like other molecular abnormalities seen in hematolymphoid malignancies, abnormalities in lncRNA expression do not seem highly specific for a particular disease state. Rather, they may contribute to cellular proliferation and/ or quiescence, and these functions may be shared across different cell types. We did not review the literature on other malignancies derived from the hematolymphoid system, including lymphoma and chronic lymphocytic leukemia, but there are a few profiling and functional studies in these other diseases as well [136] [137] [138] .
There are further studies underway that seek to delineate global lncRNA alterations during malignant hematopoietic development. In this vein, it will be extremely important to facilitate the development and implementation of bioinformatics pipelines to standardize lncRNA discovery and profiling in various disease states. As RNA species that are generally expressed at lower levels than protein-coding mRNAs, highly accurate methods of discovery are called for [18] . It will also be of great interest to define how dysregulation of certain lncRNAs seen in two or more diseases specifically contributes to the pathogenesis of a particular disease. For example, ANRIL, which is dysregulated in both AML and ALL, may function differently in these different contexts. The use of appropriate in vitro and in vivo disease models is therefore of paramount importance.
In terms of molecular mechanisms, additional work remains to be completed. The diversity of cellular functions ascribed to lncRNAs makes this a daunting task (Figure 1) . However, the studies to date provide important clues as to how to proceed on this front. First, the subcellular localization of a lncRNA seems to be an important predictor of function. The majority of lncRNAs that function as modifiers of transcriptional and epigenetic mechanisms seem to be localized to the nucleus. Cytoplasmic lncRNAs may function in post-transcriptional gene expression regulation, and mechanistic studies should be guided by such knowledge of putative functions. In addition, work that relates lncRNA expression to a particular dysregulated transcription factor will help characterize upstream regulatory mechanisms and help develop an integrated picture of lncRNA function.
Future areas of clinical development include prospective trials to validate the use of lncRNAs as diagnostic and prognostic aids. Most of the studies to date have been performed on archival tissues. In this regard it is important to consider testing platforms and the use of appropriate control samples. For example, recent advances in RNA sequencing may render this a better platform for high-throughput testing than traditional microarrays. For small numbers of lncRNAs, it may be possible to perform qRT-PCR to characterize expression levels. In addition to the diagnostic/prognostic area, it would seem that lncRNAs are an excellent area for novel therapeutic development. Targeting via siRNAs has been shown in a number of studies to date, and seems to be a viable method of knocking down lncRNAs. Improvements in delivery technologies promise to pave the way for lncRNA-interfering therapeutics as a novel method of fighting hematopoietic malignancies in the future.
Key Points
• Long noncoding RNAs are regulators that play crucial roles in hematopoietic development. Dysregulation of lncRNAs has been implicated in hematopoietic malignancies such as myelodysplastic syndrome, myeloproliferative neoplasms, acute myeloid leukemia, and acute lymphoblastic leukemia. Here we discuss lncRNAs that contribute to the pathogenesis of these diseases.
